ATG2B

Across TCGA pan-cancer cohorts, ATG2B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATG2B data layer compared with 23 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ATG2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATG2B expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where ATG2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	0.973	0.824	.003	19	view →
CCRCC	DFS	Tertile	III,IV	0.849	0.520	.014	9	view →
PDAC	OS	Quartile	All	0.424	0.725	.015	7	view →
LUAD	DFS	Median	III,IV	0.332	0.716	.011	3	view →
UCEC	OS	Median	All	0.981	0.917	.042	2	view →
GBM	OS	Tertile	All	0.262	0.581	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATG2B–LSCC (OS)

Open the LSCC breakdown →